AEON — AEON BIOPHARMA INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About AEON BIOPHARMA INC (AEON)
AEON BIOPHARMA INC (AEON) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $12,806. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in AEON
How many top investors track AEON
Only 1 tracked investor report this position.
AEON Ownership Composition
How AEON BIOPHARMA INC is held across tracked investor types, based on reported 13F positions.
- Other100.0%
Tracked investors reporting AEON
- Ken GriffinDec 31, 2025Citadel AdvisorsShares11.6KValue$12.8K% Portfolio0.00%
Recent activity
- Sold$0(-100.00%)May 15, 2026
- New$12.8KFeb 17, 2026
Frequently asked questions
- How many institutional investors hold AEON?
- 1 tracked institutional investor disclosed a position in AEON (AEON BIOPHARMA INC) in their most recent 13F filing.
- Who is the largest institutional holder of AEON?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in AEON, valued at $12,806.
- Did institutional ownership of AEON increase or decrease?
- Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 fully exited AEON.
- Where does this AEON ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.